Exagen
Vista
About Exagen
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. Exagen was established in 2002 and is headquartered in Vista, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $367.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2025)
- Ticker: nasdaq:XGN
- Website: exagen.com
- Phone: 888-452-1522
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/exagen-33045 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.